Variable name;level;Overall;Adjuvant;NAC;p;test
;n;1357;744;611;;
Age;[0 -30);95;40 (42.1);55 (57.9);NaN;
;[30 -35);246;102 (41.6);143 (58.4);;
;[35 -40);460;240 (52.2);220 (47.8);;
;40+;554;361 (65.2);193 (34.8);;
Age (mean);;38.7 [34.9, 41.6];39.7 [36.0, 42.0];37.5 [33.7, 40.7];<0.001;nonnorm
Number of children;0;373;172 (46.2);200 (53.8);NaN;
;1;279;153 (54.8);126 (45.2);;
;More than 1;705;419 (59.5);285 (40.5);;
BMI;<18.5;79;45 (57.7);33 (42.3);NaN;
;25-29.9;257;127 (49.6);129 (50.4);;
;>=30;107;56 (52.3);51 (47.7);;
;18.5-24.9;807;451 (55.9);356 (44.1);;
BMI (mean);;22.6 [20.5, 25.5];22.5 [20.4, 25.2];22.8 [20.5, 25.9];0.081;nonnorm
Treatment center;Curie Paris;818;421 (51.5);397 (48.5);NaN;
;Curie St Cloud;538;323 (60.1);214 (39.9);;
;Others;0;0 (NaN);0 (NaN);;
Hereditary predisposition;No;547;252 (46.2);294 (53.8);NaN;
;Yes;140;70 (50);70 (50);;
Inflammatory BC;No;1338;744 (55.6);593 (44.4);NaN;
;Yes;18;0 (0);18 (100);;
Clinical Tumor size (mm);;30.3 (21.7);20.4 (16.0);42.2 (21.7);"NA";
Clinical N stage (TNM);N0;854;540 (63.2);314 (36.8);NaN;
;N1;482;195 (40.5);286 (59.5);;
;N2;7;0 (0);7 (100);;
;N3;3;0 (0);3 (100);;
SBR grade;Grade I;58;47 (81);11 (19);NaN;
;Grade II;528;331 (62.7);197 (37.3);;
;Grade III;760;358 (47.2);401 (52.8);;
Histological type;NST;1265;666 (52.7);598 (47.3);NaN;
;Lobular;54;50 (92.6);4 (7.4);;
;Others;36;27 (75);9 (25);;
Neoajuvant chemotherapy;No;744;744 (100);0 (0);NaN;
;Yes;612;0 (0);611 (100);;
Fertility preservation discussion;No;909;543 (59.7);366 (40.3);NaN;
;Yes;447;201 (45.1);245 (54.9);;
